Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test

ABSTRACT

Introduction: The Alere i Influenza A & B assay incorporates the Nicking Enzyme Amplification Reaction technique on the Alere i instrument to detect and differentiate influenza virus (Flu) A and B nucleic acids in specific specimens.

Areas covered: The Alere i Influenza A & B assay was cleared by the US Food and Drug Administration for use with nasal swabs (NS) and nasopharyngeal swabs, either directly or in viral transport medium. Notably, direct use on NS was the first ever CLIA-waived nucleic acid-based test. Previously published evaluations have reported sensitivities and specificities of 55.2–100% and 62.5–100% for Flu A and 45.2–100% and 53.6–100% for Flu B, respectively.

Expert commentary: The Alere i Influenza A & B assay provides a rapid and simple platform for detection and differentiation of Flu A and B. Efforts are expected to further improve sensitivity and user-friendliness for effective and widespread use in the true point-of-care setting.

KEYWORDS:

• Influenza viruses A and B
• isothermal nucleic acid amplification technology
• nasal swabs
• nasopharyngeal swabs
• nicking enzyme amplification reaction
• rapid molecular diagnosis

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

The study was supported in part by a research agreement between the Memorial Sloan Kettering Cancer Center and Alere Scarborough (SK2013-0262) and by an NIH/NCI Cancer Center Support Grant P30 (CA008748).